Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents

Overview of attention for article published in Frontiers in Medicine, June 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 11 news outlets
blogs: 1 blog

twitter: 2 X users
patent: 1 patent

Citations

dimensions_citation: 67 Dimensions

Readers on

mendeley: 107 Mendeley

Summary News Blogs X Patents Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 16,527 followers.

@Biotech2k1 @TwistBioscience @emilylmullin @WIRED The antibodies don’t work well enough…there are published studies. I believe one theory is that they cannot access tissue resident Bcells…but haven’t followed too closely until now. https://t.co/hVkBZ

27 Sep 2022

Reply Repost Favourite

New Research: Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents: Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that a candidate… https://t.co/3joLt9GN6K #medicalcare

07 Jul 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.